New Risk • Jun 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Major Estimate Revision • May 19
Consensus EPS estimates fall by 26% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CN¥1.41b to CN¥1.34b. Losses expected to increase from CN¥0.54 per share to CN¥0.68. Biotechs industry in China expected to see average net income growth of 39% next year. Consensus price target of CN¥91.38 unchanged from last update. Share price fell 11% to CN¥50.94 over the past week. Announcement • Apr 23
Dizal Pharmaceutical Reports Key Progress in Its Nsclc Portfolio with Oral Presentations and Poster During Asco 2026 Dizal announced that new clinical data from its non-small cell lung cancer (NSCLC) pipeline will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29–June 2 in Chicago. The presentations will feature the company's investigational assets ZEGFROVY (sunvozertinib), golidocitinib, and DZD6008, highlighted by two oral presentations, including one selected as a Late-Breaking Abstract (LBA). Results from the multinational Phase 3 WU-KONG28 study of ZEGFROVY have been selected for oral presentation as an LBA. ZEGFROVY is an oral, irreversible, and highly selective EGFR tyrosine kinase inhibitor (TKI), approved in China and the U.S. for the treatment of relapsed or refractory NSCLC harboring EGFR exon20ins. WU-KONG28 is a phase 3 randomized pivotal study comparing sunvozertinib vs. chemo doublet in previously untreated NSCLC patients with EGFR exon20ins mutation. Earlier, Dizal announced that the study had met its primary endpoint with statistically significant and clinically meaningful improvement in progression-free survival (PFS). Updated clinical data of DZD6008 in pretreated NSCLC patients with EGFR C797X mutations have also been selected for oral presentation. DZD6008 is a novel, highly selective fourth-generation EGFR TKI with full blood-brain barrier (BBB) penetration, designed to address clinical challenges after treatment failure from third-generation EGFR TKIs. In preclinical models, DZD6008 exhibits potent and consistent inhibitory activity across a broad range of EGFR mutations, including EGFR driver mutations (L858R and exon 19 deletions), resistant double mutations (including T790M/C797S in the context of L858R or exon 19 deletion), and the challenging triple mutations (C797X plus T790M plus L858R or exon 19 deletion). Dizal will present the latest findings from a study evaluating golidocitinib in combination with anti–PD-1 antibody in NSCLC without known driver mutations. Golidocitinib is the world's first and only approved JAK1 inhibitor for relapsed or refractory peripheral T-cell lymphoma. Preclinical data indicate that JAK inhibition can rescue exhausted T-cell function and modulate the tumor microenvironment, providing a mechanistic basis for the combination of golidocitinib with anti-PD-1/PD-L1 therapies in NSCLC patients who have progressed on prior anti-PD-1 containing regimens. Dizal presentation details during 2026 ASCO: Lead Author Prof. John Heymach Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28) Publication Number: LBA8500 Oral Abstract Session May 29, 2026, 1:00 PM-4:00 PM CDT Prof. Mengzhao Wang DZD6008, a 4th Generation EGFR TKI, in Pretreated NSCLC Patients with EGFR C797X Mutations: Results from Phase 1/2 Studies Publication Number: 8520 Rapid Oral Abstract Session May 30, 2026, 1:15 PM-2:45 PM CDT Prof. Jie Wang Combination of golidocitinib (a JAK1 inhibitor) with anti–PD-1 antibody to improve tumor response and patient quality of life: Preliminary results from an ongoing JACKPOT 33 study Publication Number: 8555 Poster Session May 31, 2026, 9:00 AM-12:00 PM CDT ZEGFROVY is an irreversible EGFR inhibitor discovered by Dizal scientists targeting a wide spectrum of EGFR mutations with wild-type EGFR selectivity. ZEGFROVY is approved in the U.S. and China for the treatment the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), whose disease has progressed on or after platinum-based chemotherapy. The approval in China is based on the results of the pivotal WU-KONG6 study in platinum-based chemotherapy pretreated NSCLC with EGFR exon20ins. The U.S. approval is supported by WU-KONG1 Part B, a multinational pivotal study investigating the efficacy and safety of ZEGFROVY in the same indication. ZEGFROVY also demonstrated encouraging anti-tumor activity in NSCLC patients with EGFR sensitizing, T790M, and uncommon mutations, as well as HER2 exon20ins. ZEGFROVY showed a well-tolerated and manageable safety profile in the clinic. The most common drug-related TEAEs (treatment-emergent adverse event) were Grade 1/2 in nature and clinically manageable. WU-KONG28, a multinational, randomized Phase 3 study conducted across 16 countries and regions evaluating ZEGFROVY as first-line treatment for patients with EGFR exon20ins NSCLC, met its primary endpoint. Pre-clinical and clinical results of ZEGFROVY were published in peer-reviewed journals Cancer Discovery, The Lancet Respiratory Medicine and Journal of Clinical Oncology. Golidocitinib is currently the first and only Janus kinase 1 (JAK1) inhibitor being evaluated for the treatment of r/r PTCL. 
